Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK of Zibrofusidic Acid Cream in Impetigo/SITL
NCT00758862Phase 2Completed
- Sponsor
- LEO Pharma
- Start
- Dec 2008
- Primary completion
- Feb 2009
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of zibrofusidic acid in impetigo and post-traumatic wound infection, sponsored by LEO Pharma. Primary endpoints: TD1414 Serum Concentration by Timepoint, Peak TD1414 Serum Concentration and 2 more. Started Dec 2008; status: completed.
02
Drugs
zibrofusidic acid
03
Conditions
impetigopost-traumatic wound infection
Beyond the preview
Go deeper on NCT00758862.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00758862.